Aims: Surgical aortic valve replacement has been the treatment of choice for patients with aortic valve disease before the arrival of transcatheter aortic valve replacement (TAVI), although limited by degeneration of the bioprosthesis. “Redo” intervention itself is burdened by high risk of complications and valve-in-valve (ViV) TAVI could be a valid strategy of redo for patients with comorbidities. Methods and results: Two independent reviewers screened all studies investigating patients undergoing ViV TAVI. Mortality at 30 days and at 1 year was the primary end point. Of 286 studies identified, 26 articles were included in this review with a total of 1448 patients. Median age was 78.8 years, 57.7% male. Median STS score and Logistic EuroSCORE were 9.4% and 31.3% respectively. Stenosis (45%) was the leading cause of prosthesis failure. Transfemoral approach was preferred (76%), with a prevalence of balloon expandable valves (73.3%). Mean follow up was 376 days. Overall and cardiovascular mortality at 30 days was 6.5% and 5.5% respectively, while at 1 year it was 14.5% and 8.9% respectively. At meta-regression analysis study year (p <.001), Logistic EuroSCORE (p <.01) and valve diameter ≤ 21 mm (p <.05) at 30 days, and stenosis as reason for failure (p =.05) at 1 year were identified as possible predictors of survival. Conclusions: ViV TAVI offers a valid strategy to treat high risk patients with a failure of bioprosthesis with satisfying results in terms of short and mid-term mortality. Future studies are needed to find predictors of long term survival and outcomes in lower risk patients.

Incidence, predictors and outcomes of valve-in-valve TAVI: A systematic review and meta-analysis

Bruno F.;Conrotto F.;Saglietto A.;D'Ascenzo F.;Grosso Marra W.;Camboni D.;Salizzoni S.;La Torre M.;Rinaldi M.;De Ferrari G.
2020-01-01

Abstract

Aims: Surgical aortic valve replacement has been the treatment of choice for patients with aortic valve disease before the arrival of transcatheter aortic valve replacement (TAVI), although limited by degeneration of the bioprosthesis. “Redo” intervention itself is burdened by high risk of complications and valve-in-valve (ViV) TAVI could be a valid strategy of redo for patients with comorbidities. Methods and results: Two independent reviewers screened all studies investigating patients undergoing ViV TAVI. Mortality at 30 days and at 1 year was the primary end point. Of 286 studies identified, 26 articles were included in this review with a total of 1448 patients. Median age was 78.8 years, 57.7% male. Median STS score and Logistic EuroSCORE were 9.4% and 31.3% respectively. Stenosis (45%) was the leading cause of prosthesis failure. Transfemoral approach was preferred (76%), with a prevalence of balloon expandable valves (73.3%). Mean follow up was 376 days. Overall and cardiovascular mortality at 30 days was 6.5% and 5.5% respectively, while at 1 year it was 14.5% and 8.9% respectively. At meta-regression analysis study year (p <.001), Logistic EuroSCORE (p <.01) and valve diameter ≤ 21 mm (p <.05) at 30 days, and stenosis as reason for failure (p =.05) at 1 year were identified as possible predictors of survival. Conclusions: ViV TAVI offers a valid strategy to treat high risk patients with a failure of bioprosthesis with satisfying results in terms of short and mid-term mortality. Future studies are needed to find predictors of long term survival and outcomes in lower risk patients.
2020
316
64
69
Aortic stenosis; Heart team; Transcatheter aortic valve implantation; Valve-in-valve
Giordana F.; Bruno F.; Conrotto F.; Saglietto A.; D'Ascenzo F.; Grosso Marra W.; Dvir D.; Webb J.; D'Onofrio A.; Camboni D.; Grubitzsch H.; Duncan A.; Kaneko T.; Toggweiler S.; Latib A.; Nerla R.; Salizzoni S.; La Torre M.; Trompeo A.; D'Amico M.; Rinaldi M.; De Ferrari G.
File in questo prodotto:
File Dimensione Formato  
1-s2.0-S0167527319359510-main.pdf

Accesso riservato

Tipo di file: PDF EDITORIALE
Dimensione 427.37 kB
Formato Adobe PDF
427.37 kB Adobe PDF   Visualizza/Apri   Richiedi una copia

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/2318/1767874
Citazioni
  • ???jsp.display-item.citation.pmc??? 2
  • Scopus 13
  • ???jsp.display-item.citation.isi??? 11
social impact